Organization (Industry)
SMITH & NEPHEW PLC
ClinicalTrials.gov lists SMITH & NEPHEW PLC as lead sponsor of 159 trials, counting the companies grouped under it. SMITH & NEPHEW PLC itself has 9 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 2 in 2026 and about 4 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 2 already registered with a 2026 start date: at the cutoff, 1 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.
Logo Smith & Newphew, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers SMITH & NEPHEW PLC and 2 companies grouped under it: 159 lead-sponsored trials (133 its own, 26 in the grouped companies) and 7 legal-entity registrations (7 its own, 0 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Smith & Nephew Orthopaedics AG | 26 | 0 |
| T.J. Smith and Nephew, Limited | 0 | 0 |
Disease areas (63)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Osteoarthritis | 43 |
| Fractures, Bone | 14 |
| Osteoarthritis, Knee | 12 |
| Arthritis, Rheumatoid | 10 |
| Diabetes Mellitus | 9 |
Showing 5 of 63 disease areas.
Trials by start year as sponsor or collaborator (29)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 5 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 11 |
| 2021 | 7 |
| 2020 | 9 |
| 2019 | 19 |
| 2018 | 14 |
| 2017 | 17 |
Showing 10 of 29 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| total knee arthroplasty | Osteoarthritis | Not reported | 1 |
| total knee arthroplasty | Arthritis, Rheumatoid | Not reported | 1 |
| Conventional | Osteonecrosis | Not reported | 1 |
| Conventional | Fractures, Bone | Not reported | 1 |
| Standard of Care Treatment | Varicose Ulcer | Not reported | 1 |
Showing 5 of 9 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Standard Care | 3 |
| COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | 3 |
| SoloSite® | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 59% hit target (n=68) | 44% on time (n=64) |
Journals published in (48)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of bone and joint surgery. American volume | 11 |
| Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association | 8 |
| The Journal of arthroplasty | 4 |
| Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA | 3 |
| The American journal of sports medicine | 3 |
Showing 5 of 48 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2,304 | 604 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 6,164,000,000 | 625,000,000 | 296,000,000 |
| 2024 | 5,810,000,000 | 412,000,000 | 289,000,000 |
| 2023 | 5,549,000,000 | 263,000,000 | 339,000,000 |
| 2022 | 5,215,000,000 | 223,000,000 | 345,000,000 |
| 2021 | 5,212,000,000 | 524,000,000 | 356,000,000 |
| 2020 | 4,560,000,000 | 448,000,000 | 307,000,000 |
| 2019 | 5,138,000,000 | 600,000,000 | 292,000,000 |
| 2018 | 4,904,000,000 | 663,000,000 | 246,000,000 |
| 2017 | 4,765,000,000 | 767,000,000 | 223,000,000 |
| 2016 | 4,669,000,000 | 784,000,000 | 230,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (152)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-08-04 | Other financing | not disclosed | Sec extracted |
| 2026-08-04 | Debt financing | not disclosed | Sec extracted |
| 2026-07-06 | Other financing | not disclosed | Sec extracted |
| 2026-06-03 | Debt financing | not disclosed | Sec extracted |
| 2026-05-21 | Other financing | not disclosed | Sec extracted |
Showing 5 of 152 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | 2045 |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | 36.0% |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Henry Ford Health | Co sponsors trial with | 1 |
| Smith & Nephew Orthopaedics AG | Co sponsors trial with | 1 |
Latest dated events (2,667)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-10 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-08-04 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-08-04 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 2,667 events.
Biomarker capability evidence (60)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACAT1 | Trial sponsor | Named in trial inclusion criteria |
| AKR1C1 | Trial sponsor | Named in trial inclusion criteria |
| AKR1C1 | Trial sponsor | Named in trial inclusion criteria |
| AKR1C1 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 60 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.